Αποτελέσματα αναζήτησης - Sumati Gupta

  • Εμφανίζονται 1 - 18 Αποτελέσματα από 18
Περιορισμός αποτελεσμάτων
  1. 1
    Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells

    Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells από Sumati Gupta, Alexis Weston, Jared Bearrs, Trason Thode, Adrianne Neiss, Raffaella Soldi, S. Sharma

    Έκδοση 2016
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  2. 2
    Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications

    Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): pot... από Andrew W. Hahn, David Gill, Benjamin L. Maughan, Archana Agarwal, Lubina Arjyal, Sumati Gupta, Jessica Streeter, Erin Bailey, Sumanta K. Pal, Neeraj Agarwal

    Έκδοση 2017
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  3. 3
    Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

    Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harbori... από Andrea Necchi, Damien Pouessel, Raya Leibowitz‐Amit, Aude Fléchon, Sumati Gupta, Philippe Barthélémy, Michele Maio, Xinhua Zhu, Ekatherine Asatiani, Gul Serbest, Hui‐Ling Zhen, Yohann Loriot

    Έκδοση 2018
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  4. 4
    Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers

    Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers από Chadi Hage Chehade, Yeonjung Jo, Georges Gebrael, Nishita Tripathi, Nicolas Sayegh, Beverly Chigarira, Vinay Mathew Thomas, Gliceida Galarza Fortuna, Arshit Narang, Patrick Campbell, Sumati Gupta, Benjamin L. Maughan, Soumyajit Roy, Neeraj Agarwal, Umang Swami

    Έκδοση 2024
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  5. 5
    Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US

    Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US από Vinay Mathew Thomas, Yeonjung Jo, Nishita Tripathi, Soumyajit Roy, Beverly Chigarira, Arshit Narang, Georges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, Gliceida Galarza Fortuna, Richard Ji, Patrick Campbell, Haoran Li, Neeraj Agarwal, Sumati Gupta, Umang Swami

    Έκδοση 2024
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  6. 6
    First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

    First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and met... από Rom S. Leidner, Kevin C. Conlon, Douglas G. McNeel, Andrea Wang‐Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia B. Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica O’Keeffe, Nancy Lewis, George N. Pavlakis, John A. Thompson

    Έκδοση 2023
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  7. 7
    TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

    TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhi... από Yohann Loriot, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Aude Fléchon, Rohit Jain, Sumati Gupta, Manojkumar Bupathi, Philippe Beuzeboc, Phillip L. Palmbos, Arjun Vasant Balar, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, M. Sierecki, Hao Zhou, Petros Grivas, Philippe Barthélémy, Scott T. Tagawa

    Έκδοση 2024
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  8. 8
    Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3

    Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3 από Petros Grivas, Damien Pouessel, Chandler H. Park, Philippe Barthélémy, Manojkumar Bupathi, Daniel P. Petrylak, Neeraj Agarwal, Sumati Gupta, Aude Fléchon, Chethan Ramamurthy, Nancy B. Davis, Alejandro Recio‐Boiles, Cora N. Sternberg, Astha Bhatia, Cabilia Pichardo, Mitch Sierecki, Julia Tonelli, Huafeng Zhou, Scott T. Tagawa, Yohann Loriot

    Έκδοση 2024
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  9. 9
    Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)

    Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT) από Gliceida Galarza Fortuna, Daniel Grass, Benjamin L. Maughan, Rohit K. Jain, Christopher Dechet, Julia Beck, E. Schüetz, Alejandro Sánchez, Brock O’Neil, Michael Poch, Roger Li, Shane Lloyd, Jonathan D. Tward, Tenzin Kunsang Phunrab, Josiah Hawks, Umang Swami, Kenneth M. Boucher, Neeraj Agarwal, Sumati Gupta

    Έκδοση 2025
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  10. 10
    Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results

    Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results από Sumanta K. Pal, Dean F. Bajorin, Nazlı Dizman, Jean Hoffman‐Censits, David I. Quinn, Daniel P. Petrylak, Matthew D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A. Burris, Harris S. Soifer, Gary Li, Hao Wang, Carl Dambkowski, Susan Moran, Siamak Daneshmand, Jonathan E. Rosenberg

    Έκδοση 2020
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  11. 11
    Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes

    Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes από Petros Grivas, Amir Mortazavi, Joel Picus, Noah M. Hahn, Matthew I. Milowsky, Lowell L. Hart, Ajjai Alva, Joaquim Bellmunt, Sumanta K. Pal, Richard Bambury, Peter H. O’Donnell, Sumati Gupta, Elizabeth A. Guancial, Guru Sonpavde, Demiana Faltaos, Diane Potvin, James G. Christensen, Richard C. Chao, Jonathan E. Rosenberg

    Έκδοση 2018
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  12. 12
    Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

    Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) από Petros Grivas, Yohann Loriot, Rafael Morales‐Barrera, Min Yuen Teo, Yousef Zakharia, Susan Feyerabend, Nicholas J. Vogelzang, Enrique Grande, Nabil Adra, Ajjai Alva, Andrea Necchi, Alejo Rodríguez‐Vida, Sumati Gupta, Debra H. Josephs, S. Srinivas, Kenton Wride, Daleen Thomas, Andrew D. Simmons, Andrea Loehr, Rachel L. Dusek, Dale Nepert, S. Chowdhury

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  13. 13
    Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

    Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer από Matthew D. Galsky, Amir Mortazavi, Matthew I. Milowsky, Saby George, Sumati Gupta, Mark T. Fleming, Long H. Dang, Daniel M. Geynisman, Radhika Walling, Robert Alter, Mohamad Kassar, Jue Wang, Shilpa Gupta, Nancy B. Davis, Joel Picus, George Philips, David I. Quinn, G. Kenneth Haines, Noah M. Hahn, Qianqian Zhao, Menggang Yu, Sumanta K. Pal

    Έκδοση 2020
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  14. 14
    Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

    Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... από Charles M. Rudin, Hardev Pandha, Matthew R. Zibelman, Wallace Akerley, Kevin J. Harrington, Daphne Day, Andrew G. Hill, Steven O’Day, Timothy Clay, Gavin Wright, Ross Jennens, David E. Gerber, Jonathan E. Rosenberg, Christy Ralph, David C. Campbell, Brendan D. Curti, Jaime R. Merchan, Yixin Ren, Emmett V. Schmidt, Lisa Guttman, Sumati Gupta

    Έκδοση 2023
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  15. 15
    Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA

    Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA από Neeraj Agarwal, Sumanta K. Pal, Andrew W. Hahn, Roberto Nussenzveig, Gregory R. Pond, Sumati Gupta, Jue Wang, Mehmet Asım Bilen, Gurudatta Naik, Pooja Ghatalia, Christopher Hoimes, Dharmesh Gopalakrishnan, Pedro C. Barata, Alexandra Drakaki, Bishoy M. Faltas, Lesli A. Kiedrowski, Richard B. Lanman, Rebecca J. Nagy, Nicholas J. Vogelzang, Kenneth M. Boucher, Ulka N. Vaishampayan, Guru Sonpavde, Petros Grivas

    Έκδοση 2018
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  16. 16
    Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

    Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors από Kevin C. Conlon, Dionysios C. Watson, Thomas A. Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K. Felber, Cody J. Peer, William D. Figg, E. Lake Potter, Mario Roederer, Douglas G. McNeel, John A. Thompson, Sumati Gupta, Rom S. Leidner, Andrea Wang‐Gillam, Nehal S. Parikh, Debby Long, Sema Kurtuluş, Lang Ho Lee, Niladri Roy Chowdhury, Florent C. Bender, George N. Pavlakis

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  17. 17
    NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021

    NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021 από Efrat Dotan, Louise C. Walter, Ilene Browner, Katherine Clifton, Harvey Jay Cohen, Martine Extermann, Cary P. Gross, Sumati Gupta, Genevieve Hollis, Joleen M. Hubbard, Reshma Jagsi, Nancy L. Keating, Elizabeth R. Kessler, Thuy T. Koll, Beatriz Korc‐Grodzicki, June M. McKoy, Sumi Misra, Dominic H. Moon, Tracey L. O’Connor, Cynthia Owusu, Ashley Rosko, Marcia M. Russell, Mina S. Sedrak, Fareeha Siddiqui, Amy Stella, Derek L. Stirewalt, Ishwaria M. Subbiah, William P. Tew, Grant R. Williams, Liz Hollinger, Giby V. George, Hema Sundar

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  18. 18
    Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with<i>FGFR3</i>Alterations

    Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with<i>FGFR3</i>Alterations από Sumanta K. Pal, Jonathan E. Rosenberg, Jean Hoffman‐Censits, Raanan Berger, David I. Quinn, Matthew D. Galsky, Juergen Wolf, Christian Dittrich, Bhumsuk Keam, Jean‐Pierre Delord, Jan H.M. Schellens, Gwénaëlle Gravis, Jacques Médioni, Pablo Maroto, Virote Sriuranpong, Chaiyut Charoentum, Howard A. Burris, Viktor Grünwald, Daniel P. Petrylak, Ulka N. Vaishampayan, Eliahu Gez, Ugo De Giorgi, Jae‐Lyun Lee, Jens Voortman, Sumati Gupta, Sunil Sharma, Amir Mortazavi, David J. Vaughn, Randi Isaacs, Katie Parker, Xueying Chen, Kun Yu, Dale Porter, Diana Graus Porta, Dean F. Bajorin

    Έκδοση 2018
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:

Εργαλεία αναζήτησης: